Lyell Immunopharma Inc (LYEL)
2.07
-0.01
(-0.48%)
USD |
NASDAQ |
Jun 21, 16:00
2.06
-0.01
(-0.48%)
After-Hours: 20:00
Lyell Immunopharma Net Income (Annual): -234.63M for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | -234.63M |
December 31, 2022 | -183.12M |
December 31, 2021 | -250.22M |
Date | Value |
---|---|
December 31, 2020 | -204.47M |
December 31, 2019 | -129.38M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-250.22M
Minimum
2021
-129.38M
Maximum
2019
-200.36M
Average
-204.47M
Median
2020
Net Income (Annual) Benchmarks
GlycoMimetics Inc | -36.90M |
Candel Therapeutics Inc | -37.94M |
Eliem Therapeutics Inc | -35.12M |
Entrada Therapeutics Inc | -6.685M |
NovaBay Pharmaceuticals Inc | -9.64M |